BDSX vs. DCGO, FLGT, SBC, CELC, INNV, EHAB, PSNL, AIRS, LFMD, and VMD
Should you be buying Biodesix stock or one of its competitors? The main competitors of Biodesix include DocGo (DCGO), Fulgent Genetics (FLGT), SBC Medical Group (SBC), Celcuity (CELC), InnovAge (INNV), Enhabit (EHAB), Personalis (PSNL), AirSculpt Technologies (AIRS), LifeMD (LFMD), and Viemed Healthcare (VMD). These companies are all part of the "healthcare" industry.
Biodesix vs.
DocGo (NASDAQ:DCGO) and Biodesix (NASDAQ:BDSX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, community ranking, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.
DocGo has higher revenue and earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.
DocGo has a net margin of 4.35% compared to Biodesix's net margin of -66.84%. DocGo's return on equity of 8.90% beat Biodesix's return on equity.
DocGo has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.Comparatively, Biodesix has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500.
56.4% of DocGo shares are owned by institutional investors. Comparatively, 21.0% of Biodesix shares are owned by institutional investors. 2.7% of DocGo shares are owned by company insiders. Comparatively, 69.2% of Biodesix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
DocGo presently has a consensus target price of $6.10, suggesting a potential upside of 27.35%. Biodesix has a consensus target price of $3.06, suggesting a potential upside of 246.94%. Given Biodesix's higher possible upside, analysts clearly believe Biodesix is more favorable than DocGo.
DocGo received 16 more outperform votes than Biodesix when rated by MarketBeat users. Likewise, 75.00% of users gave DocGo an outperform vote while only 74.36% of users gave Biodesix an outperform vote.
In the previous week, DocGo had 7 more articles in the media than Biodesix. MarketBeat recorded 8 mentions for DocGo and 1 mentions for Biodesix. Biodesix's average media sentiment score of 0.97 beat DocGo's score of 0.32 indicating that Biodesix is being referred to more favorably in the news media.
Summary
DocGo beats Biodesix on 11 of the 16 factors compared between the two stocks.
Get Biodesix News Delivered to You Automatically
Sign up to receive the latest news and ratings for BDSX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biodesix Competitors List
Related Companies and Tools
This page (NASDAQ:BDSX) was last updated on 2/22/2025 by MarketBeat.com Staff
Free BDSX Stock Alerts